Home → E-shop → Nucleotides → Abacavir triphosphate – CAS 137820-58-7

Abacavir triphosphate – CAS 137820-58-7

Abacavir triphosphate – CAS 137820-58-7 is synthesised by Sigut Labs (Prague, Czech Republic).

Purity (LC-MS)

97%+

Package contents

Abacavir triphosphate – Et₃NH⁺salt

This compound is for research use only. We do not sell to patients.

Amount

1 mg	€ 450	Stock
5 mg	€ 1100	Stock
Do you want custom amount?			Custom amount

Amount

1 mg

€ 450

Stock

5 mg

€ 1100

Stock

Do you want custom amount?

Custom amount

Characterisation

CAS: 137820-58-7

IUPAC name: ((1S,4R)-4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)cyclopent-2-en-1-yl)methyl tetrahydrogen triphosphate

Other names: Abacavir TP; ABAC-TP

Molecular weight: 526.27 g/mol

Molecular formula: C₁₄H₂₁N₆O₁₀P₃

InChI: InChI=1S/C14H21N6O10P3/c15-14-18-12(17-9-2-3-9)11-13(19-14)20(7-16-11)10-4-1-8(5-10)6-28-32(24,25)30-33(26,27)29-31(21,22)23/h1,4,7-10H,2-3,5-6H2,(H,24,25)(H,26,27)(H2,21,22,23)(H3,15,17,18,19)/t8-,10+/m1/s1

Description

Abacavir triphosphate (ABAC-TP) is a crucial metabolite of the antiviral drug Abacavir, widely used in HIV treatment regimens. ABAC-TP is the primary active form of Abacavir within the body. This means it’s the form that directly fights the HIV virus. ABAC-TP works by inhibiting an enzyme called reverse transcriptase, which is essential for HIV to replicate and spread within the body. By hindering viral replication, ABAC-TP contributes to the effectiveness of Abacavir in managing HIV infection. Researchers studying HIV treatment mechanisms and the development of new antiretroviral therapies often utilize ABAC-TP to understand its antiviral properties.

Chemicals are distributed worldwide

Buy Abacavir triphosphate now, and get your order in 48 hours

Shipping through DHL in 48 hours
Sensitive compounds are shipped on dry ice
All compounds are safely and rigorously packed

Payment

Payment terms 30 days net
We are sending the invoice the same day as the shipment
We are able to modify the invoice for the academic institution, so the order can be paid from grants

References

Singh, D., McMillan, J., Hilaire, J., Gautam, N., Palandri, D., Alnouti, Y., … & Edagwa, B. (2016). Development and characterization of a long-acting nanoformulated abacavir prodrug. Nanomedicine, 11(15), 1913-1927.
Boojamra, C. G., Parrish, J. P., Sperandio, D., Gao, Y., Petrakovsky, O. V., Lee, S. K., … & Mackman, R. L. (2009). Design, synthesis, and anti-HIV activity of 4′-modified carbocyclic nucleoside phosphonate reverse transcriptase inhibitors. Bioorganic & Medicinal Chemistry, 17(4), 1739-1746.
Gendelman, H. E., McMillan, J., Bade, A. N., Edagwa, B., & Kevadiya, B. D. (2019). The promise of long-acting antiretroviral therapies: from need to manufacture. Trends in microbiology, 27(7), 593-606.